Vibrato Medical Closes $4M Series A Funding Round and Receives $1.5M NIH Grant
- Vibrato Medical
MONTIRVINE, Calif.–(BUSINESS WIRE)–Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that it has closed a $4M Series A funding round led by the Horowitz Group, a multi-asset class family investment office based in Newport Beach, CA, and has also received a $1.5M National Institutes of Health (NIH) grant. Together, funding will support the clinical trial of the company’s novel, noninvasive, wearable device designed to treat patients with critical limb ischemia (CLI), an advanced stage of PAD, from the convenience of their home. Read more…
Related Reading
News / Business Development / Government & Legislative Affairs / Small Business
AdvaMed Welcomes House Passage of Legislation Restoring Programs That Jumpstart Early-stage Medtech Innovation
March 17, 2026
WASHINGTON—AdvaMed, the Medtech Association, today applauded House of Representatives passage of S. 3971, the Small Business Innovation and Economic Security Act, legislation reauthorizing the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. House passage follows Senate passage earlier this month, bringing the restoration of these initiatives one step closer to completion.
News / Business Development / Small Business
AdvaMed® Welcomes Senate Passage of Legislation Restoring Programs That Jumpstart Early Stage Medtech Innovation
March 4, 2026
WASHINGTON—AdvaMed, the Medtech Association, today welcomed Senate approval of legislation reauthorizing the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs and urged the House of Representatives to act swiftly on passage.
News / Radiation Therapy / Small Business
ABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver Cancer
February 26, 2026
HALIFAX, NS, Feb. 24, 2026 /PRNewswire/ – ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced the completion of patient enrollment in its pivotal U.S. FDA Investigational Device Exemption (IDE) study, ROUTE90. The study evaluates Eye90 microspheres®, a novel Yttrium-90 (Y90) radioembolization device, for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.
News / Orthopedic / Small Business
ATRO Medical Secures €3 Million to Advance Artificial Meniscus Toward Pivotal Studies
February 24, 2026
ATRO Medical, the Dutch clinical-stage orthopedic company developing a novel artificial meniscus implant for patients suffering from post-meniscectomy pain, today announces the successful closing of a €3 million financing round. The financing round is primarily composed of equity investments, complemented by non-dilutive funding. It brings together MedTech investors from the Netherlands, Switzerland, and the United Arab Emirates such as 819 Capital, Thuja Capital, Bolwork International Investment and industry leaders DSM-Firmenich Ventures and Samaplast.
Resource / Artificial Intelligence (AI) / Coverage & Payment / Digital Health / Regulatory Affairs
AdvaMed® Comment Letter to ASTP/ONC: Accelerating AI Adoption in Clinical Care
February 24, 2026
AdvaMed’s® Comment Letter to ASTP/ONC, outlines concrete policy reforms across FDA oversight, CMS payment pathways, and HIPAA data-sharing rules to accelerate patient access to AI-enabled medical technologies. As AI-enabled medical devices transform patient care, outdated regulatory, coverage, and privacy frameworks are slowing the pace of adoption.
News / Artificial Intelligence (AI) / Regulatory Affairs
i-GENTIC AI Launches Context-Aware MedTech Agents to Strengthen FDA 510(k) Submission Consistency
February 23, 2026
PALO ALTO, Calif., Feb. 11, 2026 i-GENTIC AI today announced a new suite of context-aware, multilingual MedTech agents designed to help medical device manufacturers improve the quality and consistency of FDA 510(k) submissions. Preparing a 510(k) often takes months, yet many submissions require additional information requests or are rejected due to inconsistencies across documents, evidence, and claims, creating delays and added costs for manufacturers.
Blog / Regulatory Affairs
Why Practical FDA Submissions Training Makes the Difference
February 17, 2026
Explore AdvaMed’s Medical Device Submissions Workshop Series from practical submission strategies to live expert insights you can apply immediately.
Blog / Coverage & Payment
The Pulse of Medtech Payment: Join Us at the 2026 Payment Policy Forum
February 13, 2026
The 2026AdvaMed® Payment Policy Forum takes place May 28–29 in Washington, D.C. at Hogan Lovells Office. Registration is now open, and as always,AdvaMed® members receive preferred pricing.